Evidence map›Paper›PMID 31653830›Full record

ArticleNature communications2019

Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction.

Sarah McLaughlin, Brian McNeill, James Podrebarac, Katsuhiro Hosoyama, Veronika Sedlakova, Gregory Cron, David Smyth, Richard Seymour, Keshav Goel, Wenbin Liang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. A BACH1 inhibitor ameliorates myocardial infarction and limb ischemia in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  8. Article
  9. [Advances in hydrogel drug delivery systems for myocardial infarction treatment].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Mass Spectrometry Imaging of Biomaterials.Materials (Basel, Switzerland) · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sarah McLaughlinBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.
Brian McNeillBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.
James PodrebaracBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.
Katsuhiro HosoyamaBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.
Veronika SedlakovaBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.ORCID http://orcid.org/0000-0003-2291-4164
Gregory CronDepartment of Radiology, Faculty of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H8L6, Canada.
David SmythCardiac Function Laboratory, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.
Richard SeymourBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.
Keshav GoelBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.ORCID http://orcid.org/0000-0001-8084-9298
Wenbin LiangDepartment of Cellular & Molecular Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON, K1H8M5, Canada.
Katey J RaynerCardiometabolic microRNA Laboratory, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.
Marc RuelBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada.
Erik J SuuronenBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada. esuuronen@ottawaheart.ca.
Emilio I AlarconBioEngineering and Therapeutic Solutions (BEaTS), Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin street, Ottawa, ON, K1Y4W7, Canada. ealarcon@ottawaheart.ca.ORCID http://orcid.org/0000-0001-5100-6179

Funding

CIHR
6 · The paper itself

Abstract

Despite the success of current therapies for acute myocardial infarction (MI), many patients still develop adverse cardiac remodeling and heart failure. With the growing prevalence of heart failure, a new therapy is needed that can prevent remodeling and support tissue repair. Herein, we report on injectable recombinant human collagen type I (rHCI) and type III (rHCIII) matrices for treating MI. Injecting rHCI or rHCIII matrices in mice during the late proliferative phase post-MI restores the myocardium's mechanical properties and reduces scar size, but only the rHCI matrix maintains remote wall thickness and prevents heart enlargement. rHCI treatment increases cardiomyocyte and capillary numbers in the border zone and the presence of pro-wound healing macrophages in the ischemic area, while reducing the overall recruitment of bone marrow monocytes. Our findings show functional recovery post-MI using rHCI by promoting a healing environment, cardiomyocyte survival, and less pathological remodeling of the myocardium.

Indexed as

AnimalsCapillariesCarbodiimidesCell ProliferationCell SurvivalCicatrixCollagen Type ICollagen Type IIICoronary VesselsCross-Linking ReagentsDimethylaminesHeartHumansMacrophagesMiceMonocytesCarbodiimidesCollagen Type ICollagen Type IIICross-Linking ReagentsDimethylaminesN-ethyl-N'-(3-(dimethylamino)-propyl)carbodiimideN-hydroxysuccinimideRecombinant ProteinsSuccinimides

Identifiers

PMID31653830
PMCPMC6814728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.